Skip to content

CLINICAL RELEVANCE MAKES ALL THE DIFFERENCE: Leveraging Orthotopic PDX Models in Translational Oncology

11:30 AM EDT | 8:30 AM PDT | 4:30 PM BST | 5:30 PM CEST
Next-generation targeted anticancer therapies demand advanced preclinical models that recapitulate the tumor microenvironment. Research shows that advanced orthotopic patient-derived xenograft (PDX) models:
  • Accurately predict drug response, drug resistance and metastatic proliferation
  • Reliably mirror the behavior of cancer in their human counterparts, at an accelerated pace — making them clinically relevant patient avatars for evaluating cancer therapies
Developing orthotopic PDX models involves surgically implanting a very small sample of human tumor tissue in the corresponding anatomic location (colon, brain, pancreas, liver, lung, etc.) of specialized immunodeficient NOG mice, effectively creating a living model of that unique cancer. Certis scientists have spent years perfecting the art of orthotopic PDX engraftment, using novel surgical techniques and sophisticated animal husbandry protocols to optimize cohort viability.  
 
Join us live, as Certis Oncology Chief Scientific Officer Jonathan Nakashima discusses how to move the most promising drug candidates forward to clinic efficiently and effectively with advanced orthotopic PDX models of cancer.    
 
Attend this webinar to learn:
  • How the tumor microenvironment factors into selecting optimal cancer model(s) for your preclinical in vivo pharmacology study
  • How orthotopic PDX models combined with live in situ imaging (like mouse MRI) can accurately predict drug response, drug resistance and metastatic proliferation
  • About the need for clinically relevant solid tumor models for the translation of T cell-based therapies into the clinic
  • How orthotopic PDX models can be used to validate artificial intelligence predictions in drug discovery and development
  • How personalized orthotopic PDX of an individual’s cancer can be used as a functional testing platform

Register to Attend

This webinar is a joint presentation of Taconic Biosciences and Certis Oncology.  By submitting your registration you agree that Taconic may share your contact information with Certis, and that both Taconic and Certis may contact you for follow up.

Dr. Jonathan Nakashima

CSO, Certis Oncology

Dr. Jonathan Nakashima is the CSO of Certis Oncology, where he oversees the R&D initiatives, patient-directed orthotopic PDX pharmacology studies, and the development and implementation of translational oncology assays for drug development. Dr. Nakashima has more than 15 years of experience developing preclinical oncology models. Under a California Institute for Regenerative Medicine fellowship, he received his doctorate in Molecular and Medical Pharmacology at UCLA, where he developed genetically engineered and patient-derived xenograft models to study cancers of the central and peripheral nervous systems. He continued with his post-doctoral training in the Department of Neurobiology, where he received a Kirschstein National Research Service Award to study the cell interactions in the brain-tumor microenvironment. 

Visit Certis Oncology.

© 2024 Taconic Biosciences, Inc. All rights reserved.

Consent Preferences